Tokyo, May 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061320) titled 'Real-World Comparison of Tirzepatide and Semaglutide in Patients with Type 2 Diabetes' on May 1.
Study Type:
Observational
Primary Sponsor:
Institute - Kimitsu Chuo Hospital
Condition:
Condition - Type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The aim of this study is to compare the effects of semaglutide and tirzepatide on eating behavior and treatment satisfaction among patients with type 2 diabetes in real-world clinical practice in Japan using existing treatment cohorts.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - Patients with type 2 diabetes who were receiving treatment during the study period, were considered by the treating physician to be appropriate candidates for treatment with semaglutide or tirzepatide, and provided written informed consent for study participation.
Key exclusion criteria - Patients from whom written informed consent for study participation could not be obtained
Target Size - 200
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2026 Year 04 Month 19 Day
Date of IRB - 2026 Year 04 Month 19 Day
Anticipated trial start date - 2026 Year 04 Month 19 Day
Last follow-up date - 2026 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070158
Disclaimer: Curated by HT Syndication.
